stockrow
Friday 6 November 2026
Export CGON’s income statement to Excel — free account
CG Oncology, Inc.
CGON Healthcare Biotechnology
CG Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, up 254.7% from fiscal 2024.
- Revenue
- −3.72%
- EPS
- −12.3%
- Free cash flow
- −25.2%
- Total debt
- 0.00%
Quarter to September 2026, against a year earlier
76.08
11.28
+17.41%
Follow CGON
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 6 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
713.89 | 1,116.58 | 1,006.20 | 1,021.74 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(88.62) | (100.46) | (135.02) | (132.06) | |
P/B ratio |
4.26 | 5.24 | 6.09 | 6.36 | |
Price to Tangible BV |
4.33 | 5.29 | 6.15 | 6.43 | |
EV/Sales |
551.48 | 908.84 | 843.02 | 864.03 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(18.73) | (29.10) | (29.42) | (28.45) | |
EV/FCF |
(18.72) | (29.02) | (29.28) | (28.16) | |
Quick Ratio |
24.09 | 30.60 | 21.78 | 21.20 | |
Current Ratio |
24.63 | 31.30 | 22.22 | 21.70 | |
Net Debt/EBITDA |
15.76 | 16.80 | 11.76 | 0.00 | |
Debt/Assets |
0.38% | 0.26% | 0.28% | 0.29% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.01 | 0.01 | 0.01 | |
Operating CF/Net income |
0.88 | 0.95 | 0.59 | 0.84 | |
Capex/Depreciation |
0.00 | (0.12) | 0.57 | 0.00 | |
Research and Development Expense of Revenue |
1,290.22% | 4,037.86% | 4,724.03% | 2,445.20% | |
Selling, General and Administrative Expense of Revenue |
774.89% | 1,918.74% | 2,504.41% | 1,431.61% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
309.52% | 597.78% | 1,238.89% | 527.18% | |
Graham Net Nets |
0.22 | 0.19 | 0.16 | 0.15 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(4.99%) | (3.44%) | (3.79%) | (3.89%) | |
Free Cash Flow Yield |
(4.13%) | (2.80%) | (2.86%) | (3.00%) | |
Revenue per Share |
0.03 | 0.01 | 0.01 | 0.02 | |
Operating CF per Share |
(0.47) | (0.67) | (0.53) | (0.54) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | |
Free Cash Flow per Share |
(0.47) | (0.68) | (0.53) | (0.55) | |
Cash per Share |
9.60 | 12.73 | 11.66 | 11.08 | |
Shareholders Equity per Share |
9.74 | 12.92 | 11.67 | 11.15 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
9.74 | 12.92 | 11.67 | 11.15 | |
Free Cash Flow |
(36.22) | (57.25) | (46.88) | (48.82) | |
Working Capital |
728.64 | 1,066.93 | 1,002.41 | 961.30 | |
Capital Expenditures |
(0.01) | (0.30) | (0.47) | (1.11) | |
Net Current Asset Value |
720.49 | 1,058.66 | 993.11 | 952.03 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.28 | 0.40 | 0.70 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.73 | 0.81 | 0.49 | — | |
Average Payables |
6.12 | 7.48 | 9.93 | 9.48 | |
Average Inventory |
— | — | — | 1.33 | |
Average Assets |
773.19 | 931.72 | 893.55 | 888.29 | |
Average Common Equity |
742.99 | 898.27 | 849.74 | 839.30 |
Columns are period end dates · fundamentals updated 6 Nov 2026